Frontage outlines plan to split businesses among Charles River, Tigermed and chairman Song Li
CRL•
CRL•Frontage outlined a proposed breakup in which Charles River Laboratories would acquire its Exton operations, Tigermed would take its China business and Acme Bioscience operations, and chairman Song Li would own the remaining operations outside China. The plan remains subject to shareholder and regulatory approvals and customary closing conditions.
Frontage outlined a plan on November 16, 2026, following a November 9 transaction announcement. Charles River Laboratories would acquire Frontage’s bioanalysis and drug metabolism and pharmacokinetics operations in Exton, Pennsylvania; Tigermed would take the China business and operations owned by Acme Bioscience or its subsidiaries; and chairman Song Li would own the remaining operations outside China, including those businesses outside Exton. Completion is subject to shareholder and regulatory approvals and customary closing conditions.